Welcome to our dedicated page for Wiley (JOHN) & Sons news (Ticker: WLYB), a resource for investors and traders seeking the latest updates and insights on Wiley (JOHN) & Sons stock.
John Wiley & Sons, Inc. publishes authoritative research, learning, and professional content for researchers, students, instructors, professionals, institutions, and corporations. Company news commonly covers Research Publishing, Research Solutions, academic and professional learning products, journal portfolio expansion, and partnerships that license Wiley scientific and medical content for AI-enabled research and clinical tools.
Recurring updates also include quarterly earnings releases, margin and cash-flow commentary, AI and data services activity, capital allocation through dividends and share repurchases, and leadership changes tied to research, learning, data, and AI operations.
Wiley (NYSE: WLY) declared a quarterly cash dividend of $0.355 per share, payable April 23, 2026, to holders of record April 7, 2026, equal to an annualized $1.42 per share (up from $1.41 in Fiscal 2025).
The company also increased its Fiscal 2026 share repurchase allocation to $100 million (up from $60 million in Fiscal 2025 and $45 million in Fiscal 2024). On March 5, 2026, Wiley reported Q3 Fiscal 2026 results citing momentum in Research and AI, margin expansion, and cash flow growth.
Wiley (NYSE: WLY) reported Q3 FY2026 results: GAAP revenue of $410M (+1%), operating income $63M (+21%), GAAP EPS $0.56 vs loss prior year, and adjusted EPS $0.97 (+19% at constant currency).
Adjusted operating income rose 22% with a 280 basis-point margin expansion; adjusted EBITDA margin reached 25.7%. Free cash flow improved to $56M YTD and the company is on track for ~$200M FCF in FY2026. AI and Research momentum continued with $7M AI revenue in the quarter and multi-year partnerships announced. Share repurchases increased, targeting $100M for the full year.
Wiley (NYSE: WLY) and OpenEvidence announced a strategic partnership on March 3, 2026 to license Wiley’s scientific and medical content into OpenEvidence’s AI clinical platform.
The agreement covers the Cochrane Database of Systematic Reviews, Cochrane Clinical Answers, and over 400 Wiley journals and books, broadening point-of-care, source-cited evidence for clinicians.
Wiley (NYSE: WLY) will release third quarter 2026 results before market open on March 5, 2026 and hold a conference call at 10:00 AM ET the same day. Investors can access a live webcast at the company Investor Relations site or dial in via provided US, Canada, and international numbers with participant code 2521217#.
The company said the call will discuss the Q3 2026 results and related business updates.
Wiley (NYSE: WLY) will expand its Advanced journals portfolio into life, health and social sciences, planning to launch eight new journals by end of 2026 and additional titles thereafter. The move extends the portfolio beyond materials science and adds titles such as Advanced Oncology, opening for submissions next month.
The portfolio uses a streamlined editorial model where authors submit once and editors place papers across journals to reduce resubmission and formatting cycles, and Wiley is co-sponsoring the MD Anderson Cancer and Neuroscience Symposium Feb 19–20.
Wiley (NYSE: WLY) announced on January 13, 2026 that Armughan Rafat has been appointed chief AI and data services officer, reporting to CEO Matt Kissner and joining the executive leadership team. Rafat will lead commercialization of AI-ready content and data products for AI developers and corporate R&D teams. Wiley highlighted progress in AI monetization, including nearly $100 million in AI licensing revenue since January 2024, partnerships with Anthropic, AWS, Perplexity and Mistral AI, subscription licensing deals with R&D companies, and the launch of Wiley’s AI Gateway platform. The hire is presented as a step to scale AI-driven, high-margin data and intelligence offerings.
Wiley (NYSE: WLY) declared a quarterly cash dividend of $0.355 per share on Class A and Class B common stock, payable January 15, 2026 to shareholders of record on December 30, 2025. The quarterly payment equals an annual dividend of $1.42 per share, up from $1.41 in fiscal 2025; the company raised its dividend in June 2025 for the 32nd consecutive year.
Wiley also increased its fiscal 2026 share repurchase allocation to $100 million (from $60 million in fiscal 2025 and $45 million in fiscal 2024). On December 4, 2025 Wiley reported second-quarter fiscal 2026 results noting strong Research growth, AI demand, and a reaffirmed fiscal 2026 earnings and cash flow outlook.
Wiley (NYSE: WLY) increased its Fiscal 2026 share repurchase allocation to $100 million, up from $60 million in Fiscal 2025 and $45 million in Fiscal 2024. The company has executed approximately $35 million year-to-date and aims to execute the remaining $65 million through the fiscal year ending April 30, 2026.
Wiley also reported Q2 Fiscal 2026 highlights: 250 basis points adjusted operating margin improvement to 18.8%, reaffirmed guidance of Adjusted EBITDA margin 25.5%–26.5%, Adjusted EPS $3.90–$4.35, and Free Cash Flow ~ $200 million (vs $126M in Fiscal 2025). Board-approved repurchase authorization was raised to $250 million.
Wiley (NYSE: WLY) reported Q2 FY2026 results for the quarter ended October 31, 2025: Revenue $422M (includes $3M foregone from divestitures), GAAP Operating Income $73M (+14%), GAAP EPS $0.84 (+14%). On an adjusted basis, revenue was $422M (‑1% at constant currency), Adjusted Operating Income $79M (+14%), Adjusted EBITDA $115M (+8%) with margin 27.3% (+240 bps), and Adjusted EPS $1.10 (+12%).
Research revenue was $279M (+6%) with AI licensing projects; Learning revenue was $143M (‑11%) due to retail and consumer softness. Net debt/EBITDA was 2.0x. Wiley raised buybacks and dividends (Q2 return $40M; repurchases $21M) and narrowed FY2026 revenue guidance to low-single digit growth while reaffirming margin, EPS, and FCF targets.
Wiley (NYSE: WLY and WLYB) will release its second quarter 2026 results prior to market open on Thursday, December 4, 2025. The company will host a conference call to discuss results at 10:00 AM ET the same day.
Investors can access a live webcast at investors.wiley.com or directly via the provided Q4 events link. US and Canada dial-in is (888) 210-3346 with participant code 2521217#; international dial-in is (646) 960-0253 with the same participant code.